YOLFTbeta
Biosergen AS

Biosergen AS

BIOSGN · ST · Healthcare / Biotechnology

0.494SEK-0.00 (-0.40%)

Price History

Full chart

Market Stats

Previous Close0.496
Open0.50
Day Range0.466 – 0.50
52-Week Range0.494 – 53.80
Volume164.77K
Market Cap41.76M
P/E (TTM)0.00
Forward P/E0.00
EPS-1.51
Dividend Yield0.00%
Beta-0.08
50-Day Avg1.68
200-Day Avg18.11

About

Biosergen AB (publ), a biotech company, develops antifungal drugs. Its lead product is BSG005, an antifungal drug candidate for the treatment of invasive fungal infections in immunocompromised patients, including AIDS, cancer, and transplant recipients. The company was founded in 2004 and is based in Solna, Sweden.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMs. Tine Kold Olesen Ph.D.
  • Employees1
  • HeadquartersFogdevreten 2, Solna, Sweden, 171 65, Sweden
  • Websitehttps://www.biosergen.net

Leadership

  • Ms. Tine Kold Olesen Ph.D.CEO & Member of Executive Board
  • Mr. Mark BeveridgeChief Financial Officer · b. 1978
  • Mr. Sergey B. Zotchev Ph.D.Chief Scientific Officer and Member of Scientific Advisory Panel

Financials

Income Statement

Currency: SEK2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue1.31M4.43M8.57M0000
Growth (%)-+237.29%+93.43%-100.00%---
Cost of Revenue-10.53M178.00K280.00K456.00K00
Gross Profit1.31M-6.10M-178.00K-280.00K-456.00K00
Gross Margin100.00%-137.55%-2.08%----
Operating Expense6.47M130.00K33.90M33.85M26.81M20.69M41.39M
Operating Income-5.16M-6.23M-34.08M-34.13M-27.27M-20.69M-41.39M
Operating Margin-392.39%-140.48%-397.50%----
EBITDA-188.00K-6.23M-34.08M-34.05M228.00K-19.20M-40.84M
EBITDA Margin-14.31%-140.48%-397.50%----
Net Income-5.42M-7.22M-34.56M-34.05M-27.04M-19.20M-40.82M
Net Income Margin-412.48%-162.95%-403.10%----
R&D3.70M11.00M-----
R&D as % of Total Revenue281.35%248.13%-----
Interest Expense76.36K0240.00K54.00K9.00K78.00K10.00K
Interest Expense % of Total Revenue5.81%0.00%2.80%----

Balance Sheet

Currency: SEK2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets6.68M4.80M29.49M33.79M7.20M52.85M19.83M
Total Liabilities11.37M15.72M9.25M11.00M5.08M3.71M8.06M
Total Equity-4.69M-10.92M20.23M22.79M2.12M48.21M11.76M
Cash5.21M589.00K21.66M29.34M1.88M50.61M15.37M
Total Debt6.60M------
Net Debt1.39M-589.00K-21.66M-29.34M-1.88M-50.61M-15.37M

Cash Flow

Currency: SEK2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-2.31M-4.58M-37.75M-29.44M-32.60M-16.63M-36.81M
Financing Cash Flow5.80M-58.83M37.12M5.14M65.36M-38.00K
Capital Expenditure0000000
Free Cash Flow-2.31M-4.58M-37.75M-29.44M-32.60M-16.63M-36.81M
FCF to OCF100.00%100.00%100.00%100.00%100.00%100.00%100.00%

Earnings

Report DateJun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Mar 31, 2023May 31, 2023Aug 14, 2023Nov 30, 2023Feb 29, 2024May 31, 2024Aug 30, 2024Nov 8, 2024Mar 5, 2025May 21, 2025Aug 20, 2025Nov 19, 2025Mar 27, 2026Mar 31, 2026
EPS Estimate-------0.37-51.00-28.00---10.00--0.00-2.00-2.00-2.00--
EPS Actual-4.49-1.38-3.08-1.03-1.63-3.34-0.40-18.00-19.00-0.17-0.08-5.00-4.00-0.03-2.00-2.00-5.00-5.00-5.31-0.58
Surprise-------8.11%64.71%32.14%--50.00%---0.00%-150.00%-150.00%--
Timing------After-hoursAfter-hoursPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market--

Key Statistics & Ratios

Market Cap41.76M
Enterprise Value41.83M
Trailing P/E0.00
Forward P/E0.00
Price / Sales188.04
Price / Book64.01
EPS-1.51
Book Value0.30
Revenue (TTM)527.00K
Gross Profit (TTM)527.00K
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-194.21%
Return on Assets-83.93%
Shares Outstanding82.68M
Shares Float1.11M
Beta-0.08
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Dec 1, 20251:100